Dr. Dan Kemp is Vice President, Head of Cell Therapies Business Development & Operations at Takeda Pharmaceuticals, leading R&D collaboration deals and transactions primarily in the oncology space. Previously, he was Senior Vice President at Beryllium, and responsible for directing drug discovery partnerships. Dan ran programmes from target validation through to clinical proof of concept at Merck Research Laboratories, and prior to that led a team at Novartis Institutes for BioMedical Research developing innovative concepts for metabolic diseases.

Dan has authored over 30 papers or book chapters, of which 24 are original research contributions. Dan received a BSc and PhD in 2000 from the University of Kent at Canterbury; he was later awarded an HHMI Research Fellowship at Harvard Medical School, where he carried out post-doctoral research.